advertisement
Abstract #75503 Published in IGR 19-2
Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications
Ban N; Siegfried CJ; Apte RSTrends in molecular medicine 2018; 24: 7-17
Glaucoma is one of the leading causes of blindness globally, and is characterized by loss of retinal ganglion cells (RGCs). Because vision loss in glaucoma is not reversible, therapeutic interventions early in disease are highly desirable. However, owing to the current limitations in evaluating glaucomatous neurodegeneration, it is challenging to monitor the disease severity and progression objectively, and to design rational therapeutic strategies accordingly. Therefore, there is a clear need to identify quantifiable molecular biomarkers of glaucomatous neurodegeneration. As such, in our opinion, molecular biomarker(s) that specifically reflect stress or death of RGCs, and which correlate with disease severity, progression, and response to therapy, are highly desirable.
Department of Ophthalmology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
Full articleClassification:
11.8 Neuroprotection (Part of: 11 Medical treatment)
2.13 Retina and retinal nerve fibre layer (Part of: 2 Anatomical structures in glaucoma)
